Lead researcher
Professor Brendan Jenkins
Main finding
Treatment with canakinumab, an antibody against IL-1beta, suppresses the development of lung cancer in individuals with athersclerosis.
Centre
Centre for Innate Immunity & Infectious Diseases
Research group
Cancer and Immune Signalling
Journal and article title
Most surprising
The study, CANTOS, was designed to assess the impact of anti-IL-1 therapy on atherosclerosis on a large cohort of individuals, however it was observed that there was a specific effect on reducing the incidence of lung cancer, yet not any other cancer.
Future implications
IL-1 therapy to now be investigated further in oncology for lung cancer
Disease/health impact
lung cancer
